Fosun Pharma: "Compound Potassium Dihydrogen Phosphate Injection" has obtained acceptance for its market approval application

Fusen Pharmaceutical's wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has submitted an application for the listing of "Compound Potassium Dihydrogen Phosphate Injection" and it has been accepted. This product is used to treat hypophosphatemia and patients requiring phosphorus supplementation for parenteral nutrition, with features such as high safety, rapid absorption, and dual phosphorus-potassium supplementation. The listing of this product will provide more treatment options for adults and children. Additionally, this product enriches Fusen Pharmaceutical's product pipeline in the field of nutritional supplements